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340B Bedfellows:
How Community Health Centers can
Successfully Contract with Chain Pharmacies to
Expand Access to Needed Medicine
Kathryn R. Watson*
INTRODUCTION

The 340B Drug Discount Program extends access to affordable outpatient
prescription drugs in the United States.' Established by Congress in 1992,
the 340B Program seeks to leverage federal dollars by requiring
pharmaceutical manufacturers that enroll in Medicaid to offer their drugs to
eligible safety net providers at a steep discount. Safety net providers eligible
to participate in the 340B Program are statutorily described as "covered
entities." 2 Community health centers (also known as Federally Qualified
Health Centers) are one type of covered entity.3 Each type of covered entity
provides health care services to underserved communities or to patients with
medical conditions that are unduly expensive to treat. By saving covered
entities money on the cost of outpatient drugs, the 340B Program allows
covered entities to expand needed health services. However, this comes at a
cost of billions of dollars annually for pharmaceutical manufacturers. Recent
growth in 340B Program participation has triggered a backlash, with
pharmaceutical manufacturers alleging abuse and raising issues before
Congress.4 In turn, the 340B Program is currently under increasing scrutiny
by the federal government and private industry, as audits of covered entities
are on the rise and Senators are questioning whether the 340B Program is

* JD, MPH, LLM. I would like to thank Michael B. Glomb, Partner at Feldesman Tucker Leifer
Fidell LLP, in particular for his mentorship, insights and encouragement.
1.
Section 340B is a section within the Public Health Service Act. 42 U.S.C. § 256b
(2010) [hereinafter § 256b].
2.
§ 256b(a)(4).
3.
See § 256b(a)(4)(A) (stating a Federally Qualified Health Center is eligible to register

as a "covered entity").
4.
See Christopher Versace, CongressionalScrutiny Over 340B Program Continues to
Grow, FORBES (Mar. 30, 2015, 5:20 PM), http://www.forbes.com/sites/chrisversace/2015/03/
30/congressional-scrutiny-over-340b-program-continues-to-grow/
(noting that Congress

recently recognized the need for "reform and transparency" within the 340B Program).
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operating as Congress intended.
After more than twenty years of the 340B Program, the responsible
governmental agency - the Office of Pharmacy Affairs (OPA) within the
Health Resources and Services Administration (HRSA) - was on the verge
of releasing a proposed MegaRegulation, which promised to address a
myriad of issues. However, the MegaRegulation was withdrawn from the
Office of Management and Budget due to a significant court setback that
undermined OPA's ability to promulgate regulations.
Congress held
hearings in March 2015 and discussed whether it should expressly delegate
legislative rule-making authority to OPA. In fact, a May 2015 proposed rider
to a health bill would have done just that, but the rider was dropped before
the bill went to a vote.
Absent express rule-making authority, the OPA repackaged the promised
MegaRegulation in to MegaGuidance. This 340B MegaGuidance was
proposed in the Federal Register on August 27, 2015, with a public comment
period that closed on October 27, 2015. While the MegaGuidance is not yet
final, I will discuss the proposal further below.
Within the 340B Program, the ability of covered entities to collaborate
with chain pharmacies is a relatively new phenomenon and is one of the areas
of the 340B Program being scrutinized. 340B contract pharmacy agreements
can be particularly valuable for community health centers to expand access
for vulnerable patient populations. However, these arrangements commonly
entail difficult negotiations.
In addition to safety net providers now
contracting with multiple pharmacies, they are also contracting with - or
being solicited to contract with - third party beneficiary managers (also
referred to as administrators or vendors) who offer to administer 340B
operations.
Participating in the 340B Program offers community health centers the
promise of enhanced revenues in an otherwise uncertain financial future
under health care reform. 6 By definition, community health centers provide
primary care to the underserved. As enhanced reimbursement for primary
care services takes effect and many of the country's uninsured obtain
coverage under the Affordable Care Act of 2010 (ACA), grant funding upon
5.
See Ellen Weaver & Lindsay Boyd, Congress Waking up to 340B Corporate Slush
Fund, THE HILL (May 26, 2015, 10:00 AM), http://thehill.com/blogs/congress-blog/
(stating that some
healthcare/242985-congress-waking-up-to-340b-corporate-slush-fund
Senators within the Senate HELP Committee, the committee that has jurisdiction over the

340B Program, have "gone on record calling for 340B reform.").
6.
See Andis Robezneiks, Reform Update: Community health centers bracefor influx of
newly insured, MODERN HEALTHCARE (Mar. 31, 2014), http://www.modernhealthcare.com/
article/20140331/NEWS/303319970/reform-update-community-health-centers-brace-forinflux-of-newly.
7.
See 42 U.S.C. § 254b(a)(1) (2010) (defining a community health center as "an entity
that serves a population that is medically underserved").
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which community health centers have relied for decades is potentially up in
the air. The 340B Program likely has a stable future as a means for
community health centers to offer their patients access to affordable drugs
and to otherwise expand needed services. Contract pharmacy arrangements
offer an opportunity to expand community health centers' participation in the
340B Program. For smaller community health centers, contract pharmacy
arrangements may be the only avenue to access the Program. However,
entering 340B territory through contract pharmacy arrangements comes with
risks. Because any noncompliance by contracted entities will be considered
the community health center's liability, community health centers must
through compliant contracts and vigilant oversight - reign in the risks that
inherently come with less direct control via contracting 340B services.
This paper sets out to: (I) examine the legislative history and fundamental
elements of the 340B Program; (II) explain the unique position of community
health centers as covered entities within the 340B Program; (III) spell out
prohibitions within the 340B Program as well as government enforcement
efforts to prevent prohibited conduct; (IV) review the origins of 340B
contract pharmacy agreements; and (V) detail benefits and hazards of
contract pharmacy arrangements for community health centers.9
I. LEGISLATIVE BACKGROUND AND FUNDAMENTALS OF THE 340B
PROGRAM

A. Legislative History of the 340B Program
The 340B Program came into existence in the aftermath of Congress
implementing the 1990 Medicaid drug rebate program.10 The Medicaid drug
rebate program requires drug manufacturers to enter into agreements with the
Secretary of the U.S. Department of Health and Human Services (HHS) to
sell their drugs to state Medicaid programs at a discount as a precondition to
having that company's drugs covered by Medicaid or Medicare Part B." An
unintended - albeit predictable - consequence of the Medicaid drug rebate

8.

See

U.S.

MANUFACTURER

Gov'T ACCOUNTABILITY OFFICE, GAO-11-836,
DRUG PRICING:
DISCOUNTS IN THE 340B PROGRAM OFFER BENEFITS, BUT FEDERAL

OVERSIGHT NEEDS IMPROVEMENT 17-18 (2011) [hereinafter GAO 2011 REPORT].
9.
As a practicing attorney, I have advised community health centers in negotiating 340B
contracts with pharmacies and third party administrators. In this paper, I share my experiences
regarding common pitfalls in these arrangements, as well as offer tips regarding the structuring
of the 340B pharmacy contracts. My opinions are my own, and they are not those of my
employer or clients. This academic article is for educational purposes only and does not
constitute legal advice.
10.
See 42 U.S.C. § 1396r-8(a) (1991).
11.
See id.; Medicare Prescription Drug, Improvement, and Modernization Act of 2003,
Pub. L. No. 108-173, 117 Stat. 2066 (extending the reach to Medicare Part B as part of this
2003 Act).
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program was that manufacturers increased their sale prices elsewhere.
In particular, safety net providers experienced over a thirty percent
increase in the price of outpatient drugs in 1991, relative to previous years
where increases averaged closer to six percent.12 Essentially, pharmaceutical
manufacturers were shifting the cost of the Medicaid drug rebate program on
to health care providers, and this shift threatened to bankrupt safety net
providers whose patients were disproportionately uninsured and
underinsured.13 Accordingly, these providers lobbied Congress for relief and
the result was the 340B Program under the Public Health Services Act.14
The purpose of the 340B Program was to provide discounts on covered
outpatient drugs to select safety net providers, including community health
centers.15 According to the legislative record, the 340B Program was
designed to permit covered entities "to stretch scarce Federal resources as far
as possible, reaching more eligible patients and providing more
comprehensive services."" In tandem with passing Section 340B, Congress
enacted Section 1927 of the Social Security Act, which requires drug
manufacturers who want their drugs covered within Medicaid to enter into an
agreement with the Secretary of HHS under which the manufacturer agrees
to comply with 340B requirements.17 In other words, the 340B Program
requires drug manufacturers to offer the same rebate they offer to state
Medicaid offices to designated providers at discounts as a pre-condition of
continuing Medicaid coverage of a manufacturer's outpatient drugs.
According to HRSA, the 340B Program provides additional financial
resources to covered entities without increasing the federal budget by
lowering drug acquisition costs while maintaining revenue from health
insurance reimbursements." Accordingly, the 340B Program is designed to
promote access to affordable medications.
Since its enactment in 1992, the 340B Program existed with little fanfare
and scant government regulation until health care reform debates raised the
Program's profile in 2010.19 In fact, OPA relied fully on discretionary

12.
H.R. REP. No. 102-384, pt. 2, at 12 (1992).
13.
See id.
14.
See Veterans Health Care Act of 1992, Pub. L. No. 102-585, §§ 601-03, 106 Stat.
4943 (1992).

15.

See § 256b.

16.

See H.R. REP. No. 102-384, pt. 2, at 12 (1992).

17.

See

HEALTH

RES.

AND

SERV.

ADMIN.,

OFFICE

OF

PHARMACY

AFFAIRS,

PHARMACEUTICAL PRICING AGREEMENT (2006), http://www.hrsa.gov/opa/manufacturers/
pharmaceuticalpricingagreement.pdf.
18.
HEALTH RES. AND SERV. ADMIN., HEMOPHILIA TREATMENT CENTER MANUAL FOR
PARTICIPATING IN THE DRUG PRICING PROGRAM ESTABLISHED BY SECTION 340B OF THE PUBLIC

HEALTH SERVICE ACT (2015), http://www.hrsa.gov/hemophiliatreatment/340Bmanual.htm.
19.
There was a U.S. Senate Bill introduced to expand the 340B Program in 2007. This
bill, S. 1376 and known as the "340B Program Improvement and Integrity Act of 2007,"
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spending for the majority of the 340B Program's history until Congress
appropriated funding for the Program for the first time in 2009.20 At this
time, Congress called for an assessment of the 340B Program, which resulted
in two key 2011 reports: a June 2011 Office of Inspector General (OIG)
report focused on duplicate discounts and a September 2011 U.S. General
Accounting Office (GAO) report focused on lax government oversight, both
of which will be discussed further below.2 1 In 2010, under the ACA,
Congress added 340B Program requirements and opportunities.2 2
Through the ACA, Congress imposed additional oversight and
transparency obligations on HRSA, specifically directing HRSA to create a
formal dispute resolution procedure, institute refund and civil penalty
systems, and perform audits of both covered entities and manufacturers.23
The ACA added a requirement for covered entities to recertify annually.24 In
turn, covered entities gained nondiscrimination protections under the ACA,
which specifically barred manufacturers from discriminating against covered
entities in the sale of 340B drugs.25 Simultaneously, Congress expanded the
340B Program under the ACA by expanding the hospital sector of covered
entities to include cancer centers and other non-profit hospitals focused on
especially vulnerable patients. 26 The ACA enhanced HRSA's enforcement
authority, and money for enforcement actions soon followed through
Congressional appropriation bills. 27 After nearly two decades of stealth
proposed covering inpatient drugs but died in committee. S. 1376, 11Oth Cong. § 3 (2007).
20.
See Omnibus Appropriations Act of 2009, Pub. L. No. 111-008, 123 Stat. 763 (2009);
see also William von Oehsen et al., The 340B Drug Discount Program: A New Era of
Enforcement and Oversight, 5 J. OF HEALTH & LIFE Sci. L. 72, 86 (2012) [hereinafter von
Oehsen Article].
21.
See DEP'T OF HEALTH AND HUMAN SERV., OFFICE OF INSPECTOR GEN., OEI-05-0900321, STATE MEDICAID POLICIES AND OVERSIGHT ACTIVITIES RELATED TO 340B-PURCHASED

DRUGS 14 (2011), http://oig.hhs.gov/oei/reports/oei-05-09-00321.pdf [hereinafter OIG 2011
REPORT]; GAO 2011 REPORT, supra note 8, at 21-32.
22.
See The Patient Protection and Affordable Care Act, Pub. L. No. 111-148, § 7101,
124 Stat. 821 (2010).
23.
See 42 U.S.C. § 256b(d) (2010).
24.
§ 256b(a)(7)(E).
25.
See § 256b(a)(1) (requiring a "ceiling price" which prohibits drug manufacturers from
offering different prices to covered entities).
26.
See § 7101(a), 124 Stat. at 821-22 (stating entities that became eligible for the 340B
Program through ACA include certain critical access hospitals, sole community hospitals,
rural referral centers, and freestanding cancer hospitals). To be eligible for the 340B Program,
rural referral centers and sole community hospitals must have a disproportionate share hospital
(DSH) adjustment percentage that is equal to or greater than 8 percent, and DSH, children's,
and free-standing cancer hospitals must have a DSH adjustment percentage that is greater than
11.75 percent. Id. Although children's and free-standing cancer hospitals do not receive
payments under the Medicare inpatient prospective payment system, they must have a payer
mix that would result in a DSH adjustment percentage of greater than 11.75 percent. GAO
2011 REPORT, supra note 8, at 9 n.25.
27.
§ 7102(a), 124 Stat. at 823-25.
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operation, the 340B Program now has its share of the limelight, and whether
that is a benefit or a detriment to various stakeholders remains to be seen.
B. Who are Covered Entities?
Section 340B identifies covered entities as disproportionate share
hospitals, community health centers, and various other safety net providers,
under a detailed list.28 These providers include twelve categories of state,
local, and private nonprofit entities that receive government funding to
provide health care to the underserved.29 Covered entities generally fall into
one of two types of providers - clinics that receive federal grants, known as
"grantees," and select hospitals.3 0 Grantees include community health
centers, Ryan White Act 31 grantees that provide HIV/AIDS services, stateoperated AIDS drug assistance programs (ADAPs), urban Indian clinics,
homeless clinics, and hemophilia diagnostic treatment centers, among
others. 32 Hospitals include disproportionate share hospitals, children's
hospitals, and cancer hospitals, among others.33
In order to participate in the 340B Program, a covered entity must not just
qualify but also must register with OPA. Upon enrollment, OPA requires
covered entities and manufacturers to certify that they will comply with 340B
requirements and associated agency guidance. 34 Additionally, as noted
above, covered entities must now recertify annually.35
The number of 340B covered entity sites has grown steadily since the
beginning of the Program. A GAO report noted that in 2001 there were 8,605
covered entity sites.36 According to one study, the 340B Program stood at
over 12,000 covered entities in 2007.37 In 2011, the GAO reports there were
16,572 covered entity sites. 38 By 2013, over 1,100 covered entities were
community health centers. 39 The GAO study reports hospitals' participation

28.
§ 256b(a)(4).
29.
Id.
Id.
30.
31.
Ryan White Comprehensive AIDS Resources Emergency Act, Pub. L. 101-381, 104
Stat. 576 (1990).
32.
Id.
33.
Id.; § 7101, 124 Stat. at 821.
34.
GAO 2011 REPORT, supranote 8, at 21.
35.
42 U.S.C. § 256b(a)(7)(E) (2010).
36.
GAO 2011 REPORT, supranote 8, at 8.
37.
Krista Werling et al., The 340B Drug PricingProgram:An Opportunityfor Savings,
if Covered EntitiesSuch as DisproportionateShare Hospitals and Federally Qualified Health
Centers Know How to Interpret the Regulations, 34 J. HEALTH CARE FIN. 57, 57 (2007)
[hereinafter Werling Article].
38.
GAO 2011 REPORT, supranote 8, at 8.

39.
GEN.,

MARY K. WAKEFIELD, DEP'T OF HEALTH AND HUMAN SERVS., OFFICE OF INSPECTOR
OEI-05-13-00431, MEMORANDUM REPORT: CONTRACT PHARMACY ARRANGEMENT IN
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in the 340B Program tripled from 2005 to 2011, a growth rate far exceeding
that of federal grantees. 40 The number of covered entities has grown at a
faster rate after HRSA approved the use of 340B contract pharmacy
arrangements.41
Pursuant to the ACA, covered entities are not only required to recertify
annually, but they must register any new pharmacy sites, including outside
contract pharmacies. 42 To recertify, a covered entity must update its listing
in the 340B database, register new facilities and contract pharmacies, update
the Medicaid Exclusion File, and attest to its compliance obligations,
including the requirement to notify OPA of any "material breach" as soon as
possible. 43 To remain in the 340B Program, a covered entity must comply
with the 340B requirements, including preventing duplicate discounts and
preventing the diversion of 340B drugs to non-eligible patients, as discussed
further below. Covered entities must also maintain auditable records and
allow compliance audits by HRSA or, with HRSA's permission, by a
manufacturer.4 4
C. What is the 340B Discount?
Participation in the 340B Program as a covered entity can achieve
significant cost savings and, in some instances, generate revenue for
community health centers. Under the 340B Program, drug manufacturers
that participate in Medicaid must provide a reduced 340B price to covered
entities that choose to enroll in the 340B Program. 45 This reduced price is
applicable only to drugs - both prescription and over-the-counter - "used in
an outpatient setting, excluding vaccines."46 The value of 340B discounts is
equivalent to the discounts that manufacturers are required to provide to state
Medicaid agencies under the Medicaid drug rebate program. In other words,
the 340B Program "draws on the larger scheme's pricing methodology" and
manufacturers "agree to charge covered entities no more than predetermined
ceiling prices, derived from the 'average' and 'best' prices and rebates

THE 340B PROGRAM 3 (2014), http://oig.hhs.gov/oei/reports/oei-05-13-00431.pdf [hereinafter
OIG 2014 MEMO].
40.
GAO 2011 REPORT, supranote 8, at 27.
41.
Id.
42.
See Overview of the 340B Drug Pricing Program, 340B HEALTH,
http://www.340bhealth.org/340b-resources/340b-program/overview
(last visited Nov. 9,
2015) [hereinafter 340B HEALTH'S Overview] (noting the covered entity's responsibility in
monitoring and reporting contract pharmacy compliance with the requirements of the 340B
Program).
43. 340B HEALTH'S Overview, supra note 42.
44.
Id.
45.
See 42 U.S.C. § 256b(a)(1) (2010).
46.
See id.; Werling Article, supra note 37, at 58.
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calculated under the Medicaid Rebate Program." 47 The discount is calculated
using the Medicaid rebate formula and is deducted from the manufacturer's
selling price rather than paid as a rebate.48
The 340B price is a calculated "ceiling" price based on a manufacturer's
"average wholesale price" (AWP) reduced by the statutorily required rebate
percentage.4 9 In a 2005 report, the Congressional Budget Office estimated
that 340B ceiling prices are equal to the Medicaid net manufacturer price,
which equals fifty-one percent of the AWP.so Although the ceiling price is
calculated by the manufacturer, the underlying AWP data has been
confidential and proprietary.51 Therefore, historically it has been impossible
for covered entities to determine whether the 340B price they are charged is
the accurate ceiling price.
To assist covered entities, the 340B statute tasked the Secretary of HHS
with establishing a prime vendor program "under which covered entities may
enter into contracts with prime vendors for the distribution of covered
outpatient drugs."52 HRSA has identified Apexus as its governmentsanctioned group purchasing organization (GPO), which is tasked with
negotiating lower 340B prices with drug manufacturers. 53 The 340B
Program prohibits hospitals from otherwise using GPOs. 54 This hospitalGPO prohibition is a great benefit to community health centers as it forces
hospitals, with their greater market leverage, to collaborate with the smaller
safety net providers in securing more favorable 340B prices. According to
the President of Apexus, hospitals account for over eighty-six percent of all
340B purchases, underscoring the value of the GPO prohibition on 340B
hospitals.
Apexus is the exclusive contractor for HRSA's 340B Prime
Vendor Program and is responsible for securing sub-ceiling discounts on
covered outpatient drugs.5 ' To benefit from this program, covered entities

47.

Astra USA, Inc. v. Santa Clara Cnty, Cal., 131 S.Ct. 1342, 1346 (2011) (holding that

the 340B "agreement" between HRSA and a manufacturer is not a transactional, bargainedfor contract, but rather a means by which drug companies opt in to the 340B statutory scheme,
and does not create third party beneficiary rights in covered entities).
48.
See 42 U.S.C. § 256b(a)(1) (2010).
49.
See id. (referring to the maximum price that covered entities may permissibly be

required to pay for the 340B drug as the "ceiling price").
50.

See CONG. BUDGET OFFICE, PRICES FOR BRAND-NAME DRUGS UNDER SELECTED

FEDERAL PROGRAMS 12 (2005), http://www.cbo.gov/sites/default/files/cbofiles/ftpdocs/64xx/
doc6481/06-16-prescriptdrug.pdf.
51.
See id. at 13.
52.
§ 256b(a)(8).
53.
340B Implementation, HEALTH RES. AND SERV. ADMIN., http://www.hrsa.gov/opal
implementation (last visited Nov. 9, 2015).
54.
See § 256b(a)(4)(L)(iii).
55.
Christopher Hatwig, President, Apexus, Address at AHA 2015 Annual Membership
Meeting: 340B Drug Pricing Program Update (May 3, 2015).
56.
See 340B Implementation, supra note 53.
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must specifically enroll in the Prime Vendor Program.s7
Covered entities have gone to court over alleged overcharging for 340B
drugs.ss In 2011, the U.S. Supreme Court denied a covered entity's attempt
to assert a private right of action against a drug manufacturer for
overcharging for 340B drugs.59 In its holding, the unanimous Court found:
Congress did not respond to the reports of inadequate HRSA enforcement
by inviting 340B entities to launch lawsuits in district courts across the
country. Instead, in the ACA, Congress.. .opted to strengthen and
formalize HRSA's enforcement authority, to make the new adjudicative
framework the proper remedy for covered entities complaining of
'overcharges and other violations of the discounted pricing requirements,'
id., at 823, 42 U.S.C. § 256b(d)(1)(A), and to render the agency's
resolution of covered entities' complaints binding, subject to judicial
review under the [Administrative Procedure Act], id., at 827, 42 U.S.C.
§ 256b(d)(3)(C). 60
As the Supreme Court noted, the ACA addresses the 340B Program's
history of inadequate government oversight.6 '
The ACA requires the
Secretary of HHS to publish "precisely defined standards" for calculating the
ceiling price, verifying the prices, and making them available to covered
entities through a secure web site.62 Covered entities should take advantage
of these new safeguards to prevent overcharging and should report any
suspected overcharging to OPA.
The Section 340B discount is important mostly for very expensive
pharmaceuticals, which are typically brand name drugs. There is also a
"ceiling price" on generic drugs purchased through the 340B Program.63
However, the methodology for calculating the ceiling price and market forces
frequently result in the open market price for generics being lower than the
340B ceiling price. 64 Thus, some covered entities may find it desirable to
purchase generics on the open market, thereby eliminating the limitations
(and compliance obligations) inherent in the 340B Program and any
anticipated costs of contracting with an outside pharmacy and/or a 340B
vendor.s
57.
58.

Id.
See Astra USA, Inc. v. Santa Clara Cnty, Cal., 131 S.Ct. 1342, 1347 (2011).

59.
60.

See id.
Id. at 1350.

61.
62.
63.

See id.
See 42 U.S.C. § 256b(d)(1)(B) (2010).
§ 256b(a)(1).
64.
JEFFREY R. LEWIS, THE FUTURE OF THE 340B DRUG PRICING PROGRAM: CHALLENGES
AND OPPORTUNITIES 13 (2011).
65.
See id. (noting that "covered entities are able to purchase generics on the open market
at less than the 340B ceiling price").
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The National Association of Community Health Centers found that
community health centers save between fifteen and sixty percent on their
prescription drug costs by using the 340B Program." In a 2011 report, the
National Association of Community Health Centers observed that the
"amount of savings per community health center depends on the volume and
type of drugs that are purchased" (i.e., brand name versus generic). 7 Some
community health centers may have a relatively large number of insured
patients, whose insurance payments for prescription medication may be
significantly greater than the community health center's purchase price,
thereby increasing the community health center's savings. Community
health centers may use any 340B-created surplus in a variety of ways, such
as expanding their formulary, expanding current services and programs,
and/or offering new services." Any 340B-generated surplus should be used
to advance the purposes of programs for which the community health center
received its federal grant.
Pharmaceutical manufacturers estimate they gave $1.0 billion worth of
340B discounts in 2005, while in 2010 the estimated discounts totaled $2.2
billion. 69 The industry projects 340B discounts will grow to $5.0 billion by
2016.70 The steep increase in discounts provided is largely attributed to the
increase in the number of participating covered entities (and dispensing
pharmacies). With costs rising, it is no surprise that pharmaceutical
companies have been increasingly vocal in pushing for 340B reform.
II. WHAT IS UNIQUE ABOUT COMMUNITY HEALTH CENTERS?

The Community Health Center program, authorized by Section 330 of the
Public Health Services Act in 1975, currently supports more than 1,300
community health centers that operate approximately 9,000 sites and serve
over 23 million patients nationwide.
Community health centers (per the
Social Security Act, "Federally qualified health centers" that are often
referred to as FQHCs) originated in the 1960s as a key part of the War on
Poverty.72 Under the ACA and due to health reform measures, community
66.
NAT'L Ass'N OF CMTY. HEALTH CTRs., UNDERSTANDING THE 340B PROGRAM: A
PRIMER FOR HEALTH CENTERS 4 (2011).
67.

Id.

68.

Id.

69.

ALLIANCE FOR INTEGRITY & REFORM OF 340B, UNFULFILLED EXPECTATIONS: AN
ANALYSIS OF CHARITY CARE PROVIDED BY 340B HOSPITALS 9 (2014), http://340breform.org/

userfiles/Final%20AIR%20340B%20Charity%2OCare%20Paper.pdf.
70.
Id.
71.

U.S. DEP'T OF HEALTH & HUMAN SERV., HEALTH CENTER FACT SHEET, http://

bphc.hrsa.gov/about/healthcenterfactsheet.pdf (last visited Nov. 8, 2015); see 42 U.S.C. §
254b (2010) (authorizing legislation).
72.
Martha J. Bailey & Andrew Goodman-Bacon, The War on Poverty's Experiment in
PublicMedicine: Community Health Centers and the Mortality of OlderAmericans, 105 AM.

https://lawecommons.luc.edu/annals/vol25/iss1/3

10

Watson: 340B Bedfellows: How Community Health Centers can Successfully Co

2016

340B Bedfellows

11I

health centers are expected to assist approximately 35 million patients by
2020.73 Accordingly, there is substantial growth and opportunity in this
sector.
Common characteristics of Section 330-supported community health
centers are that they (1) serve a designated medically-underserved area or
population, (2) are governed by patient-directors representing the majority on
the board of directors, (3) offer comprehensive primary care, preventive care,
and enabling services, and (4) serve all residents of their service area
regardless of ability to pay or insurance status.74 Community health centers
are primarily private non-profit organizations, with some community health
centers operating as public entities, where a government entity collaborates
with an independent community health center board to run a clinic.75
Organizations may obtain FQHC status in one of three ways: be awarded
a Section 330 grant to become a "grantee," enter a sub-recipient arrangement
with an existing grantee, or apply for FQHC Look-Alike status.7 ' FQHC
status brings multiple benefits including possible grant funding, safe harbor
protection under the Anti-Kickback Statute (for grantees and subrecipients),
eligibility for Federal Tort Claims Act coverage for medical malpractice
claims (for grantees and subrecipients), cost-related payment for the
provision of services to Medicaid and Medicare beneficiaries, and eligibility
- as has been established in the above sections of this paper - to participate
in the 340B Program. 77
Regardless of the approach to obtain FQHC status, all FQHCs must
comply with the legal requirements set forth under Section 330, its
implementing regulations, and agency policy from the HRSA.7 ' Among
these requirements are mandates that are frequently implicated in 340B
contract pharmacy arrangements, such as the requirement that community
health centers must offer a sliding fee scale discount to eligible patients but

EcoN. REv. 1067, 1069-70 (Mar. 2015).
73.
NAT'L. Ass'N OF CMTY. HEALTH CTRs., FREQUENTLY ASKED QUESTIONS - THE
HEALTH CENTER FUNDING CLIFF AND NACHC's PROPOSED SOLUTION, http://www.nachc.com/
client/Frequently%20Asked%20Questions%20HC%20Cliff.pdf (last visited Nov. 9, 2015).
74.
Jacqueline C. Leifer, Community Health Centers, FELDESMAN TUCKER LEIFER
FIDELL, https://www.feldesmantucker.com/programs/community-health-centers/ (last visited
Nov. 4, 2015).
75.
What is a Health Center?, HEALTH RES. & SERV. ADMIN., http://bphc.hrsa.gov/about/
what-is-a-health-center/index.html (last visited Nov. 9, 2015).
76.
CTRS. FOR MEDICARE AND MEDICAID SERVS., U.S. DEP'T OF HEALTH & HUMAN SERV.,
FEDERALLY QUALIFIED HEALTH CENTER (Jan. 2013), https://www.cms.gov/Outreach-andEducation/Medicare-Learning-Network-MLN/MLNProducts/downloads/fqhcfactsheet.pdf.
77.
NAT'L Ass'N OFCMTY. HEALTH CTRS., AFFILIATIONS BETWEEN HEALTH CENTERS AND
OTHER COMMUNITY-BASED PROVIDERS 5-6 (Aug. 2004), http://bphc.hrsa.gov/archive/
technicalassistance/resourcecenter/managementandfinance/affiliationsbetweenhealthcentersa
ndothercommunitybas.pdf.
78.
Id.
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may not otherwise give discounts to third parties.79 These requirements will
be discussed in detail in the section addressing contract terms.80
There are some community health center characteristics that simplify
340B compliance. Because community health centers are outpatient only,
they dispense only outpatient drugs, unlike hospitals that must distinguish
inpatient from outpatient prescriptions for 340B purposes. Because of their
inpatient services, hospitals are at greater risk of 340B drugs being
unlawfully diverted to non-eligible patients.
Additionally, because
community health centers are required by law to serve uninsured patients,
their participation in the 340B Program is less controversial than hospitals,
some of which have a poor track-record of charity care.
III. 340B PROGRAM PROHIBITIONS AND ENFORCEMENT

A. Prohibitionon Duplicate Discounts
Pharmaceutical manufacturers are protected from giving duplicate
discounts under 340B and within Medicaid. Section 340B prohibits covered
entities (and contract pharmacies, as applicable) from dispensing drugs
acquired at the 340B discounts to Medicaid fee-for-service patients when the
drug is also subject to a Medicaid rebate. 82 Unfortunately, communication
between covered entities and state Medicaid offices regarding duplicate
discounts has been unreliable over the years.
Section 340B tasked the Secretary of HHS with creating a mechanism for
preventing duplicate discounts, from which the Medicaid Exclusion File was
born. 83 The Medicaid Exclusion File serves as a spreadsheet that lists all
covered entities, along with their provider numbers, that use 340B drugs with
Medicaid patients.84 The 2011 OIG report regarding the 340B Program,
however, uncovered gross miscommunication between HRSA and state
Medicaid offices.85 In response to the OIG report, HRSA has increased its
outreach efforts to states concerning the agency's online databases.
Additionally, covered entities now must recertify annually, which increases

79.
See infra Part VI(iii).
80.
Id.
81.
42 U.S.C. § 254b(a)(1) (2010).
82.
42 U.S.C. § 256b(a)(5)(A)(i) (2010).
83.
See id. (noting the establishment of the 340B Medicaid Exclusion File as a way to
prevent duplicative discounts).
84.
Id.
85.
See OIG 2011 REPORT, supra note 21, at 14-15 (recognizing that some states lack
reporting methods for identifying 340B claims); see also von Oehsen Article, supra note 20,
at 90-91 (noting the OIG findings that many states did not use the Medicaid Exclusion File
and did not have an alternative method for identifying 340B claims, leading to duplicative
discounts).
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the accuracy of the Medicaid Exclusion File." The ACA also directed HRSA
to develop "more detailed guidance describing methodologies and options
available to covered entities for billing covered outpatient drugs to State
Medicaid agencies in a manner that avoids duplicate discounts,"" but such
guidance is still pending.
A concern for community health centers is whether dispensing 340B drugs
to Medicaid Managed Care Organization (MCO) patients, rather than
Medicaid fee-for-service patients, risks a duplicate discount. Billing a
Medicaid MCO at market rates for a 340B drug dispensed to a Medicaid
MCO enrollee does not appear to create a duplicate discount under Section
340B.8 At the time the methodology for preventing duplicate discounts was
published, manufacturers were not required to pay states a rebate on drugs
dispensed to Medicaid MCO enrollees. That changed with the enactment of
the ACA, which extended the manufacturers' rebate obligation to covered
outpatient drugs dispensed to individuals enrolled in a Medicaid MCO if the
Medicaid MCO is responsible for coverage of such drugs.89 However, the
ACA further amended Section 1927 of the Social Security Act to expressly
exclude Section 340B drugs from the rebate obligation.9 0 In short, since
340B drugs dispensed to Medicaid MCO enrollees are specifically exempt
from the rebate requirement, it is arguably impossible for a covered entity to
violate Section 340B by submitting a claim to a Medicaid MCO for payment
of 340B drugs.
With respect to Medicaid fee-for-service drugs, the current HRSA
pharmacy contract guidelines prohibit the use of a contract pharmacy to
dispense to Medicaid beneficiaries unless that state's Medicaid agency and
the pharmacy have developed a methodology to prevent duplicate discounts.
Effectively, for a contract pharmacy to dispense 340B drugs to Medicaid
patients, the pharmacy and state Medicaid agency must agree on a way to
determine which of the contract pharmacy's Medicaid claims were filled with
340B drugs (on behalf of the contracting covered entity) and which were not
so the state may claim a rebate for the latter. Because coordinating such an
effort is a heavy lift, most contract pharmacies opt out of providing 340B
drugs to Medicaid patients altogether.
The Medicaid Exclusion File - the mechanism that HRSA established to

86.
§ 256b(a)(7)(E).
87.
§ 256b(d)(2)(B)(iii).
88.
See § 256b(a)(5)(A)(i) ("A covered entity shall not request payment under Title XIX
of the Social Security Act [Medicaid] for medical assistance described in section 1905(a)(12)
of such Act with respect to a drug that is subject to an agreement under this section if the drug

is subject to the payment of a rebate to the State under section 1927 of such Act.").
89. 42 U.S.C. § 1396r-8(b)(1) (2008).
90.
See id. (stating that a rebate agreement is required "for covered outpatient drugs of
the manufacturer").
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prevent duplicate discounts - requires timely updates and active referencing
in order to be effective.91 HRSA requires a covered entity to notify OPA if
it is dispensing 340B drugs to Medicaid beneficiaries, and OPA then lists this
information on the Medicaid Exclusion File, which is published on the OPA
website.9
In theory, state Medicaid agencies then use the Medicaid
Exclusion File to determine which covered entity claims were filled with
340B drugs so those drugs can be excluded from the state's Medicaid rebate
claims to manufacturers.93 Nevertheless, a covered entity is liable for
duplicate discounts, begging the question of how a community health center
is supposed to force a state Medicaid agency to consistently check the
Medicaid Exclusion File. On top of its obligations to confirm that the
Medicaid Exclusion File accurately reflects its practices, a covered entity
must understand its responsibilities regarding identifying 340B claims
submitted to Medicaid MCOs. 9 4 These responsibilities are grounded in state

law and/or in Medicaid MCO contract provisions.9 5
B. Prohibitionon Diversion of 340B Drugs to Non-Eligible Patients
Under the statute, 340B drugs may be dispensed only to a "patient" of a
covered entity and may not be resold, or diverted, to non-eligible patients.96
Covered entities "shall not resell or otherwise transfer" any 340B drug "to a
person who is not a patient of the entity."97 As the prohibition hinges on the
meaning of "patient," there is an ongoing debate as to the scope of an eligible
340B patient.9 8 This issue was addressed in HRSA's proposed
MegaGuidance. The new patient definition under the proposed
MegaGuidance narrows the pool of eligible patients.99

91.
See § 256b(a)(5)(A) (establishing the duplicate discount provision for Medicaid
patients).
92.
See Final Notice Regarding Section 602 of the Veterans Health Care Act of 1992
Duplicate Discounts and Rebates on Drug Purchases, 58 Fed. Reg. 34058 (June 23, 1993)
(adopting the final mechanism as proposed).
93.
See generally HEALTH RES. AND & SERV. ADMIN., OFFICE OF PHARMACY AFFAIRS,
CLARIFICATION ON THE USE OF THE MEDICAID EXCLUSION FILE, Release No. 20143-12 (Dec.

12, 2014), http://www.hrsa.gov/opa/programrequirements/policyreleases/
clarificationmedicaidexclusion.pdf [hereinafter CLARIFICATION] ("At registration, covered
entities must inform HRSA determined whether the covered entity will purchase and dispense

340B drugs to their Medicaid patients ('carve-in') or whether they will purchase drugs for
their Medicaid patients through other mechanisms ('carve-out').").
94.

See id.

95.

Id.
§ 256b(a)(5)(B) (prohibiting diversion).

96.
97.

Id.

98.
ANDREW W. MULCAHY ET AL., RAND CORP., THE 340B PRESCRIPTION DRUG
DISCOUNT PROGRAM: ORIGINAL, IMPLEMENTATION, AND POST-REFORM FUTURE 1 (2014),

http://www.rand.org/content/dam/rand/pubs/perspectives/PE100/PE121/RANDPE121.pdf.
99.
See 80 Fed. Reg. 52300, 52306 (Aug. 28, 2015).
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At this time, prior to the MegaGuidance being finalized, a 340B eligible
patient is currently defined by statute as simply "a patient of the entity." 0 0
In 1996, HRSA issued a definition of a 340B patient.0 1 In 2007, HRSA
published a notice in the Federal Register in an effort to revise the 340B
definition of patient. 102 However, this proposal was met with such resistance
that HRSA subsequently rescinded its 2007 guidance.103 Accordingly, for
nearly two decades stakeholders looked to the broad 1996 HRSA definition
as the current program guidance on how to protect against diversion.'
HRSA's 1996 definition of a patient is broad. Under current program
guidance, a person is a "patient" of the covered entity for 340B eligibility
purposes if: (i) the covered entity has established a relationship with the
person such that the covered entity maintains records of the person's
healthcare; (ii) the person received health care services from a provider
employed by, or under a contractual or other arrangement with, the covered
entity such that responsibility for the care provided remains with the covered
entity; and (iii) the person receives a service or range of services consistent
with the service or range of services for which grant funding or FQHC LookAlike status has been provided to the entity, as applicable.1 0 5 Naturally, this
definition has been subject to various interpretations.
For community health centers, defining a 340B eligible patient is easier
than for hospital covered entities, as community health centers provide only
outpatient services thereby eliminating confusion over whether the
prescription arose from an inpatient service. Still, there have been gray areas
with the 1996 patient definition with which community health centers have
had to contend. For example, the 1996 definition mentions maintenance of
records, without specifying "medical records." 0 6 This ambiguity has led to
some organizations that play a solely administrative role with patients to
claim the individuals as 340B patients when, in fact, the organization
delivered no direct health services to the individual. This practice is
relatively straight-forward as an abuse of the 340B Program, as the Program

100.
§ 256b(a)(5)(B).
101.
Notice Regarding Section 602 of the Veterans Health Care Act of 1992 Patient and
Entity Eligibility, 61 Fed. Reg. 55156, 55156-58 (Oct. 24, 1996) [hereinafter 61 Fed. Reg.
55156] (defining "patient" for purposes of the 340B Program).
102.
Notice Regarding Section 602 of the Veterans Health Care Act of 1992 Definition
of "Patient," 72 Fed. Reg. 1543 (Jan. 12, 2007) [hereinafter 72 Fed. Reg.1543].
103.
Werling Article, supra note 37, at 64 (noting that covered entities voiced "deep

concern that HRSA's proposal is way too complicated for safety net pharmacists to implement
and that large segments of the patient populations served by safety net providers will lose

access to discounted drugs.") (citing Ctrs. for Medicare & Medicaid Servs., Industry Fears
HRSA Proposal Will Reduce Access to 340B Rx Discounts, INSIDE CMS (Jan. 25, 2007)).
104.
61 Fed. Reg. 55156, supra note 101, at 55157.

105.

Id. at 55157-58.

106.

61 Fed. Reg. 55156, supra note 101, at 55156-58.
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states that services rendered by the covered entity to the patient must be more
than the mere prescription of a 340B drug (except in the case of state-operated
ADAPs).10 7
More controversial is the use of referrals in the 340B Program. The 1996
definition requires the medical provider to be employed by, or in some "other
arrangement" with, the covered entity.108 Understandably, there has been
confusion about what entails a permissible "other arrangement." On one
hand, if a community health center refers its patient to a nearby cardiologist
who then prescribes outpatient prescription medication for a heart condition
and refers the patient back to the community health center for follow-up care,
it was arguable that this medication was - and deserves to be - 340B eligible.
Pharmaceutical companies have taken the position that HRSA should require
a direct care standard for patient eligibility, whereby the provider would have
to be employed by or a direct independent consultant to the covered entity.
This direct care standard was adopted in the proposed MegaGuidance.10 9 If
this standard survives and is reflected in the final MegaGuidance, it will
result in any prescriptions arising out of a referral relationship being beyond
the scope of the 340B Program.
The newly proposed MegaGuidance redefined patient to reign in the 340B
Program. 1 0
Indeed, the proposed MegaGuidance deleted the "other
arrangement" language used in the 1996 guidance and required the covered
entity and prescribing individual to have either an employment or
independent contractor relationship "such that the covered entity may bill for
services on behalf of the provider.""' In a less controversial move, the
proposed MegaGuidance stated that the 340B Program "does not serve as a
general employee pharmacy benefit or self-insured pharmacy benefit."112 In
other words, the proposal clarified that it is not sufficient for an individual to
be an employee of a covered entity to be a 340B eligible patient, but rather
that individual must be a patient.113
The proposed MegaGuidance would require "that the covered entity
maintains access to auditable health care records which demonstrate that the
covered entity has a provider-to-patient relationship, that the responsibility
for care is met for each 340B drug." 1 14 This proposed restriction was in
response to HRSA's concern that organizations were claiming 340B

107.
108.

Id. at 55158.
72 Fed. Reg. 1543, supra note 102.

109.

See 80 Fed. Reg. 52300, 52319.

110.
111.
112.
113.
114.

See id. at 52306.
Id. at 52319.
Id at 52307.
Id.
See id. at 52319.
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eligibility based on administrative services alone. 1 5 This records-related
change further solidifies the need for a nexus between covered entity services
and the prescription of 340B drug.
The proposed MegaGuidance does not reference income or insurance
status as a qualifying factor of the patient. 16 There are groups who advocate
for limiting 340B drugs to uninsured patients only, which would significantly
cut 340B savings for covered entities and, therefore, curtail the growth of
safety net programs associated with such savings. It is very unlikely that
HRSA would adopt such an extreme position as limiting 340B to uninsured
patients in the final MegaGuidance.
C

Enforcement and Sanctions under the 340B Program

Historically, the 340B Program operated with little government oversight,
partly due to the lack of enforcement measures within the statute as well as
the lack of funds for OPA to regulate the participants. Accordingly, OPA
relied on participants' certifications upon enrollment and subsequent selfpolicing.117 The authorization of contract pharmacy arrangements in 2010
opened the door to more players in the game, which increased the financial
pinch that pharmaceutical manufacturers felt." Proportionate to the cost of
the 340B Program to manufacturers has been the volume of their voice on
Capitol Hill. Manufacturers - often through the organization Alliance for
Integrity and Reform of 340B (also known as AIRx 340B) - have called on
Congress to reign in 340B.119 Through the ACA, Congress established new
sanctions for 340B Program violations.120
Pursuant to the ACA amendments to the 340B Program, failure to comply
with 340B policies may lead to corrective action, including having to issue
refunds to manufacturers, with interest, and being excluded from the 340B
Program altogether.121 HRSA may remove a covered entity from the 340B
Program if a violation was "systematic and egregious as well as knowing and
intentional."122 In addition to penalties applicable under Section 340B itself,
a violation of 340B requirements may subject a community health center to
civil and criminal sanctions under many federal laws. Generally speaking,
the laws the government would likely invoke for a 340B Program violation

115.
116.

Id.
Id.

117.

GAO 2011 REPORT, supra note 8, at 21.

118.

Id. at 10.

119.
See Core Principles, ALLIANCE FOR INTEGRITY AND REFORM OF 340B (2013),
http://www.340breform.org/page.asp?id=76.
120.
Patient Protection and Affordable Care Act, Pub. L. No. 111-148, § 7102(a), 124
Stat. 119, 821 (2010).
121.
See § 256b(d)(2)(B)(v).
122.
§ 256b(d)(2)(B)(v).
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would be false claims laws. 123 A covered entity that diverts (or permits its
vendor to divert) 340B drugs to ineligible persons, or permits (intentionally
or unintentionally) unreasonable amounts of the revenue from the dispensing
of drugs to flow to the vendor instead of using it to further the purposes of
the 340B Program, arguably has made a false claim under federal law. 124
The federal Anti-Kickback Statute may potentially be implicated by 340B
Program noncompliance. 125 Under that statute, it is a criminal offense to
knowingly offer or accept anything of value in order to induce patient
referrals under a federal health care program. 126 This statute almost invariably
comes into play in dealings involving health care providers. HRSA contract
pharmacy guidelines specifically warn against contract relationships that
could implicate the Anti-Kickback Statute. 127
While criminal penalties are not within the scope of Section 340B, there
has been an occasion when a provider has faced criminal sanctions under
other laws for acts related to 340B drug diversion. 128 In or around 2006, a
Pennsylvania physician was charged with violating the Prescription Drug
Marketing Act, which prohibits illegal wholesaling. 129 He faced up to ten
years in jail, but his trial ended in a mistrial.130 The doctor entered a
settlement with the government under which he agreed to pay $565,000 in
fines while being allowed to continue his medical practice.13 1 This example
underscores the potential reach of the government in cases involving, but not
limited to, 340B Program violations.
In September 2011, the GAO published the results of its research into the
340B Program and found that HRSA had not been exercising appropriate
oversight. 13 2 As a direct consequence of the GAO report, HRSA has
increased its random and targeted audits of both covered entities and drug
manufacturers.133 In Fiscal Year (FY) 2012, HRSA audited fifty-one
entities.13 Of the FY 2012 audits, forty-five were risk-based while six were

123.
124.
125.
126.
127.
128.
129.

See, e.g., 31 U.S.C. § 3729 (2009), et seq.
Id.
See 42 U.S.C. § 1320a-7b (2010).
Id.
Notice Regarding 340B Drug Pricing Program, infra note 206, at 10279.
Werling Article, supranote 37, at 62.
Id.

130.

Id.

131.

Id.

132.
133.

GAO 2011

REPORT, supra note

8.

HEALTH AND REs. SERV. ADMIN., STAKEHOLDERs LETTER: PROGRAM INTEGRITY

(Feb. 10, 2012), http://www.hrsa.gov/opa/programrequirements/policyreleases/
programintegrity021012.pdf.
134.
HRSA Posts Some 340B Audit Results, Am. Hosp. Ass'N., (Fed. 18, 2013), http://
www.aha.org/advocacy-issues/alliances/340B-hrsa-results.shtml.
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targeted.135 Of the fifty-one entities audited by HRSA, just ten were
community health centers.136 Risk-based audits have been triggered based
on outlier data that raised a red flag to the agency. 13 7 For example, one
community health center went from four contract pharmacies to nearly forty,
thereby raising suspicions and earning itself an audit. In another example, a
community health center experienced an uptick in 340B prescriptions that
seemed suspicious, but when the center explained to OPA that it had recently
affiliated with an HIV/AIDS provider thereby increasing its HIV/AIDS
medication prescriptions, there was no subsequent corrective action.
In FY 2012, HRSA found eighteen of the fifty-one audited covered entities
had violated the duplicate discount prohibition due to either Medicaid claims
being incorrectly coded when provided to the state or the entity having billed
Medicaid contrary to information contained in the Medicaid Exclusion
File.138 HRSA found sixteen of the audited covered entities diverted 340B
product, and seven had incorrect 340B database records.13 9 HRSA posts
summaries of its audit findings on its website.140 Accordingly, negative
findings can have a far reach in terms of a covered entity's public relations.
Section 340B specifies the processes for HRSA audits and for
manufacturer audits of covered entities. In 1996, HRSA released guidelines
for manufacturer audits. 141 The scope of a manufacturer's audit is more
limited than that of a HRSA audit. A manufacturer may audit covered entity
records concerning duplicate discounts, diversion, and whether the entity
improperly purchased orphan drugs at 340B prices. 142 Manufacturers may
conduct audits of covered entities with approval from OPA. To obtain such
approval, a manufacturer must have "reasonable cause" to believe the
135.
Webinar: 340B Drug Pricing Program Compliance Risks: Are You Prepared?
(Draffin & Tucker, LLP, Ga. HFMA-Spring Inst., May 7, 2015), http://www.georgiahfma.org/
documents/Presentations/2015/Spring%20Institute/6_Sarah%20Dekutowski_340B%20Drug
%20Pricing%20Program%20Compliance%20Risk.pdf.

136.

Christopher Hatwig, President, Apexus, Address at Nat'l Ass'n of Cmty. Health Ctr.

Policy Conference: The 340B Prime Vendor Program; Supporting All 340B Stakeholders
(Mar. 21, 2014).
137.
See Webinar: 340B Drug Pricing Program Compliance Risks: Are You Prepared?
(Draffin & Tucker, LLP, Ga. HFMA-Spring Inst., May 7, 2015), http://www.georgiahfma.org/
documents/Presentations/2015/Spring%20Institute/6_Sarah%20Dekutowski_340B%20Drug
%20Pricing%20Program%20Compliance%20Risk.pdf.

138.

HEALTH RES. AND SERV. ADMIN., PROGRAM INTEGRITY:

FY12

AUDIT RESULTS

(last

updated Oct. 29, 2015), http://www.hrsa.gov/opa/programintegrity/auditresults/
fyl2results.html.

139.

Id.

140.
141.

Id.
See Manufacture Audit Guidelines and Dispute Resolution Process, 61 Fed. Reg.
65406 (Dec. 12, 1996); HEALTH RES. AND SERV. ADMIN., HRSA POLICY RELEASE No. 2011-3,
(Nov. 21, 2011) (reiterating audit guidelines for manufacturers), http://www.hrsa.gov/opal
programrequirements/policyreleases/manufacturerauditclarification 112111 .pdf.
142.
61 Fed. Reg. 65406.
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covered entity is in violation of the diversion, duplication, or noncompliance
with the orphan drug exclusion rule. 143 In contrast, HRSA may execute
random audits. A manufacturer must also provide OPA with its audit plan,
which requires use of an independent public accountant who will perform the
audit in accordance with Government Accounting Standards, prior to
approval. 1" As of July 2013, OPA had accepted six manufacturer audit work
plans.145 Under the ACA, Congress tasked HRSA with creating a new
dispute resolution process for covered entities and manufacturers, which the
agency has yet to unveil. 146
As noted earlier, in addition to requesting and conducting audits of
covered entities, pharmaceutical manufacturers have raised a ruckus with
lawmakers. The 340B Program has come under Congressional scrutiny as
pharmaceutical companies allege that hospitals have misused the program by
applying 340B savings to programs that arguably do not provide safety net
services or do not help the underserved. For example, Senator Chuck
Grassley, ranking member of the Senate Judiciary Committee, wrote to three
large hospital systems in North Carolina seeking information about those
hospitals' participation in the 340B Program. 147 Specifically, Senator
Grassley noted their non-profit status and sought details on 340B revenues,
reinvestment of those revenues, payor mix for 340B claims, indigent care
demographics, and policies on charitable care. 148 Congressional inquiries
seem to focus on hospitals, where the sheer volume of 340B drugs acquired
is higher and risk of diversion is greater than such risks for smaller covered
entities. Regardless of the size of a covered entity, community health centers
must be mindful to utilize any surpluses to support access to affordable
medications, outcomes-driven pharmacy services, and high quality care.
Congress allocated approximately $6 million to OPA for FY 2014.149
While $6 million may be a drop in the budgetary bucket, it is a great deal
more than OPA is accustomed to receiving. These funds will likely be used

143.
Id.
144.
Id.
145. Stephanie P. Hales, 340B Compliance: Overcoming Challenges with Diversion,
Duplicate Discounts, and Orphan Drug Restrictions STRAFFORD (Jan. 15, 2014), http://
media.straffordpub.com/products/340b-compliance-overcoming-challenges-with-diversionduplicate-discounts-and-orphan-drug-restrictions-2014-01-15/presentation.pdf.
146.
Patient Protection and Affordable Care Act, Pub. L. No. 111-148, § 7102(a), 124
Stat. 821 (2010) (codified as 42 U.S.C. § 256b(d)(3)(B)(v) (2010)).
147.
Press Release, Sen. Charles E. Grassley, N.C. Hospitals Draw Attention to Concerns
in Discount Drug Program (Apr. 3, 2013), http://votesmart.org/public-statement/776135/
grassley-nc-hospitals-draw-attention-to-concerns-in#.Vfhbe84mSJV.
148.
Id.
149.
U.S. DEP'T OF HEALTH AND HUMAN SERV., FISCAL YEAR 2014 JUSTIFICATIONS OF
ESTIMATES FOR APPROPRIATIONS COMM.

(2014), http://www.hrsa.gov/aboutibudget/

budgetjustification2014.pdf.
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to increase accountability programs and, thus, covered entities will see more
audits in the near future. The FY 2015 budget is expected to deliver $17
million to OPA, where $10 million is set to come from fees imposed on 340B
participants. 15
IV. WHY WORK WITH CONTRACT PHARMACIES?

A.

The Initial 340B ProgramRestriction on Pharmacy Sites

When established, the 340B Program limited covered entities to using inhouse pharmacies or a single outside pharmacy, without allowing the use of
multiple pharmacy sites. 151 The 340B Program generally limited pharmacy
contracts to one per entity delivery site. 152 The rationale for this limitation
on a pharmacy network was to keep the 340B Program services localized to
safeguard oversight. Fewer pharmacy outlets risked fewer diversions. Over
time, however, it became clear that the limitations on pharmacy networks
kept many otherwise eligible covered entities from participating in the 340B
Program. Many smaller covered entities, mostly community health centers,
had operations too small to host an in-house pharmacy. Such community
health centers organized to push for an expansion of the 340B pharmacy
contracting possibilities. Of course, chain pharmacies also lobbied for this
expansion, seeing a business opportunity under the 340B Program. 153
B.

Opening the Door to ContractPharmacy Agreements

In 2010, HRSA issued revised guidance allowing entities to contract with
multiple pharmacies. 154 The 2010 guidelines are more liberal than previous
HRSA policy and allow covered entities to contract with chain pharmacies,
multiple community pharmacies, and Pharmacy Benefit Managers to provide
340B drugs to the entity's patients.5 5 A "contract pharmacy" is a pharmacy
dispensing 340B-purchased drugs on behalf of a covered entity.156 Contract
pharmacies may not directly purchase 340B drugs, but are merely dispensing
agents. The 2010 guidelines permit a covered entity to dispense 340B drugs
both through an in-house pharmacy and through commercial pharmacy
contracts. This guidance applies to all contract pharmacy arrangements and
replaced previous HRSA policy statements and correspondence addressing

150.
151.

Id.

152.
153.
154.

Id. at 3.
Id. at 12.
Notice Regarding 340B Drug Pricing Program, infra note 206, at 10272.

155.

Id.

156.

Id. at 10279.
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340B contract pharmacies. 1 s7

The 2010 guidance is clear: a "covered entity that wishes to utilize contract
pharmacy services to dispense section 340B outpatient drugs must have a
written contract in place between itself and a specified pharmacy.""ss In
exchange for being allowed greater reach through multiple pharmacy
arrangements, covered entities have the "responsibility to: ensure against
illegal diversion and duplicate discounts; maintain readily auditable records;
and meet all other 340B Drug Pricing Program requirements." 159 This
requirement represents HRSA's compromise to allow covered entities to
reach beyond their in-house pharmacies or one outside pharmacy. 160 HRSA
provided compliance elements and suggested contract clauses for contract
pharmacy arrangements.16
The proposed MegaGuidance supplements the 2010 guidance. 162 The
proposed MegaGuidance would require covered entities, whose contract
pharmacy arrangements are intended to dispense to Medicaid patients, to
submit such written contracts to HHS and the State Medicaid agency or MCO
for approval prior to having the contract listed on the OPA's website as an
extra measure of protection against the risk of duplicate discounts. 163
C.

Concerns with ContractPharmacyArrangements

-

In issuing its 2010 guidance, HRSA opened the door for chain pharmacies
(e.g., Walgreens, Walmart) to engage in the business of 340B drug
dispensing. Not surprisingly, the number of participating covered entities
and pharmacy sites skyrocketed. 164 HRSA originally resisted contract
pharmacy arrangements because of the increased risk of diversion and other
oversight concerns. Such arrangements also invite skepticism because they
risk sullying the legislative intent of the 340B Program if the benefits
intended for non-profit safety net providers - are being siphoned off by forprofit chain pharmacies.16 s Fortunately, many concerns about business
arrangements can be addressed through careful contracting and strong
compliance programs.
Nevertheless, as with any promising business
opportunities, there will be those who take advantage of the program.
Since 2010, when chain pharmacies were first permitted to participate in
157.

Id. at 10277.

158.

Id.

159.
160.
161.

Id. at 10277.
Id. at 10272-73.
See id. at 10277-79.

162.

See 80 Fed. Reg. 52300, 52309.

163.

See id.

164.
MEDICARE PAYMENT ADVISORY COMM'N, REPORT TO THE CONGRESS: OVERVIEW OF
THE 340B DRUG PRICING PROGRAM 10 (2015).

165.

See LEWIS, supra note 64, at 4-5.
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the 340B Program, the program has grown exponentially. According to an
OIG report, the number of unique pharmacies serving as 340B contract
pharmacies has grown by 770 percent, and the total number of contract
pharmacy arrangements has grown by 1,245 percent.166
Of the 7,000 contract pharmacies, 5,400 are Walgreens locations.167
Walgreens became a prime example of a chain pharmacy that risked abuse
of the 340B Program when, in July 2013, Senator Chuck Grassley (R-lowa)
sent a letter to the company's CEO.1 68 Senator Grassley asked the Walgreens
CEO to explain his company's participation in the 340B Program and
highlighted claims on a Walgreens' employee online profile that trumpeted
the ability of Walgreens to profit wildly off the program. 169 The LinkedInTM
page of Timothy Hong, "Senior 340B Inventory and Reconciliation Analyst"
with Walgreens, stated that Walgreens' involvement in the 340B Program "is
projected to add a minimum of $250 million in incremental revenue over the
next 5 years" and can "Optimize client's 340B program, so they can be more
profitable while lowering Walgreen's liability." 170 Additionally, Senator
Grassley quoted a Walgreens slide presentation that stated Walgreens can
"Generate revenue from your 340B patients."17 ' These claims are alarming
because the 340B Program is intended to generate revenue for, not from,
340B patients, either directly or through helping to expand safety net provider
services. Senator Grassley noted that the 340B Program "is not intended to
subsidize pharmacies that team up with covered entities to turn a profit." 17 2
Senator Grassley summarized a major concern with 340B contract
pharmacy arrangements perfectly in asking "why should Walgreens, as a forprofit corporation, financially benefit from such a program?" 173 This speaks
to the question of: what is a fair fee for pharmacies to charge covered entities
for dispensing 340B drugs? With community health centers in particular, it
is not unusual for contract pharmacies to have the upper hand in bargaining
power. 174 Commonly, pharmacies will ask for a percentage of savings for
every 340B drug dispensed, usually a term paired with a baseline flat fee to

166.

See OIG 2014 MEMO, supra note 39.
167.
Letter from Chuck Grassley, U.S. Senator, to Gregory Wasson, CEO of Walgreens
(July 31, 2013),
http://www.pembrokeconsulting.com/pdfs/Grassley_340BLettertoWalgreens31 July2Ol3.pdf (last viewed March 8, 2014).
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assure the pharmacy realizes some profit.s One trouble with percentagebased dispensing fees is that it does not reflect the work done. In other words,
it is no more work by the pharmacy staff to dispense a cheap drug than an
expensive drug.
On February 4, 2014, the OIG issued a Memorandum Report on Contract
Pharmacy Arrangement in the 340B Program, describing the results of a
survey it conducted regarding the use of contract pharmacies by covered
entities. 7 The OIG interviewed fifteen community health centers and fifteen
disproportionate share hospitals, all of which are parties to one or more 340B
contract pharmacy agreement." The report warned that "contract pharmacy
arrangements create complications in preventing duplicate discounts" and
that covered entities interviewed failed to "conduct all of the oversight
activities recommended by HRSA."" The OIG found that approximately
twenty-two percent of covered entities utilize contract pharmacies. 179 The
OIG identified significant "discrepancies" in policies and risks of diversion
in contract pharmacy arrangements.180
One concern identified in the 2014 OIG report was that covered entities
interpreted 340B eligibility differently for similarly situated patients.181 For
example, the OIG uncovered a lack of uniform determinations for
prescriptions written by doctors not directly employed by the covered entity
and refills.182 These OIG findings created further support for HRSA revising
the patient definition for purposes of the 340B Program.
Other concerns identified in the 2014 OIG memo included the treatment
of discounts for uninsured patients and variation in the oversight of 340B
contract pharmacies.1 83 Unfortunately, eight of the thirty covered entities
interviewed shared that they did not offer discounts on drugs to uninsured
patients.184 This finding should concern covered entities because one reason
the 340B Program garners strong support from Congress is that it is seen as
increasing access for the uninsured. Covered entities not providing any 340B
discounts to uninsured patients may send the wrong message. That said,
these entities did report that they reinvest 340B savings to expand health care

175.
MARK RILEY, ARKANSAS PHARMACISTS ASSOCIATION, MAKING SENSE OF THE 340B
DRUG PROGRAM (2012), http://www.arpharmacists.org/assets/documents/340b%20white%
20paper.pdf.
OJG 2014 MEMO, supra note 39.
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services. Additionally, it merits noting that only one of the eight covered
entities that failed to pass discounts on to the uninsured was a community
health center.18 5
Inconsistent oversight of 340B contract pharmacy arrangements prompted
the OIG to recommend an increase in the use of independent auditors by
covered entities. 1 6 According to the 2014 OIG Report, only seven of the
thirty covered entities interviewed had retained independent auditors."' The
majority of the remaining covered entities monitored contract pharmacies on
an ad hoc basis.' In response, the proposed MegaGuidance imposes a
requirement for covered entities to conduct annual audits using outside
independent auditors.189 The tension underlying this proposed requirement
is the dearth of experienced and qualified auditors in the 340B field.
In its 2014 memo, the OIG conceded that it did not use a representative
sample, resulting in its findings not being generalizable.190 That has not
stopped the Senators who requested the report from issuing statements
generally critical of HRSA. In the conclusion to its 2014 memo, the OIG
stated the memorandum report was issued directly in final form because it
contained no recommendations and that they are "continuing to review
contract pharmacy arrangements in the 340B Program and may include
recommendations in an upcoming report if appropriate." 191The OPA issued a
brief response to OIG's report on the same day, February 5, 2014,
emphasizing HRSA's commitment to strengthening 340B Program integrity
with a focus on contract pharmacy arrangements. 192
V. STRUCTURING CONTRACT PHARMACY AGREEMENTS

340B contract pharmacy agreements have particular requirements beyond
good business contracting principles. In fact, HRSA published contracting
"best practices" for these types of agreements, while resisting the request to
publish a model contract. Not surprisingly, HRSA's guidelines for 340B
contract pharmacy agreements focus on safeguards against diversion and
duplication.1 93 Of course, a contract can only do so much. The parties must
act in accordance with the contract and law and hold each other

185.
186.
187.
188.
189.
190.
191.

See id. at 14.
See id.
See id. at 15.
See id. at 14.
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accountable. 194
The contract should, however, clarify the parties'
understanding and act as a platform that allows the pharmacy and covered
entity to hash out details in advance so that all parties are prepared to
implement the 340B Program properly. 19 5
An added complexity to these contracts is the frequent involvement of a
third party benefits manager. 19 6 These administrators aim to help covered
entities implement 340B programs, and community health centers often find
the relationships very useful. 19 7 However, a covered entity may never believe
it has outsourced its responsibility for full compliance under the 340B
Program, as that may breed complacency when, in fact, liability to the
government and manufacturers for all violations of 340B remain with the
covered entity.198 Accordingly, an act of noncompliance by a contracted
vendor may result in penalties against the covered entity. 199
Contract pharmacies generally operate in one of two ways: the prepurchased inventory model or the replenishment inventory model.200 The
latter model appears to be more common. The pre-purchased inventory
model is where the pharmacy has stocked its shelves with the covered entity's
340B-purchased drugs.201 When that covered entity's eligible patient
presents a prescription, the contract pharmacy uses the covered entity's 340B
drugs to fill it.202 Meanwhile, that pharmacy maintains non-340B inventory
with which it fills non-340B prescriptions.20 3 In a replenishment inventory
model, the pharmacy does not keep 340B-purchased drugs in stock.204
Rather, the pharmacy fills prescriptions for the covered entity's eligible
patients with its own non-340B drugs, and then notifies the covered entity,
which purchases the quantity of the drug at the discounted 340B price and
has the drugs delivered to the contract pharmacy to "replenish" its stock.205
A typical 340B contract between a covered entity and pharmacy will
include the following sections: (i) recitals; (ii) definitions; (iii) obligations of
the covered entity; (iv) obligations of the pharmacy; (v) reimbursement and
billing (vi) records and audits; (vii) term and termination; (viii)
194.
See id. at 10279.
195.
See id.
196.
72 Fed. Reg. 1543, supra note 102, at 1545 (discussing third party case managers
and provides examples of case management constructs).
197.
See id.
198.
See id. at 1545-46.
199.
Notice Regarding 340B Drug Pricing Program, infra note 206, at 10279 (discussing
penalties for non-compliance with the Anti-Kickback Statute).
200.
WAKEFIELD, supra note 39, at 5.
201.
See id.
202.
See id.
203.
See id.
204.
See id.
205.
See id.
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miscellaneous. Beyond these contract sections, 340B contract pharmacy
agreements trigger other concerns, which will be address below under (ix).
(i)

Recitals Section

As with any contract, recitals are a place to ground the reader in
understanding the identity of the parties entering the agreement. In 340B
contracts, similar to most health care contracts, the intent of the parties is
stated in the recitals to underscore the proper business purposes behind the
agreement. For example, the contracts will often begin with the recitation
that the "covered entity desires to contract with the pharmacy to manage and
dispense covered entity's 340B drugs pursuant to the covered entity's 340B
drug program; and the pharmacy agrees to manage and dispense covered
entity's 340B drugs pursuant to the terms and conditions of this Agreement."
The recitals section of the contract is a place to recognize the parties' joint
intentions and respective roles.
(ii)

Definitions Section

Given the regulated environment of 340B contracts, a definitions section
is highly advisable. It is surprising how often covered entities must negotiate
the definitions of 340B terms. If the parties cannot agree to the meaning of
a 340B drug or eligible patient, then the arrangement should not go forward.
As discussed above, the statutory definition of an eligible 340B patient is
slim. It is wise to cross-reference the 1996 HRSA guidance in a contract's
definition of patient, while noting that the contract will incorporate any new
legal definitions of "patient". Additionally, parties may want to expressly
exclude Medicaid fee-for-service patients from the definition of "eligible
patient" to prevent risk of a duplicate discount.
When reviewing contracts, people all too frequently skim over the
definition section and those provisions in the miscellaneous section (e.g.,
notice, amendment, governing law provisions). Skimming is a mistake,
especially in a private contract - such as a 340B contract pharmacy
agreement - that extends your liability and makes you more vulnerable to
government sanctions. As a covered entity remains liable for the pharmacy's
and administrator's actions in implementing that covered entity's 340B
Program, it is crucial that management understand all of the nuances of what
it is signing up for.
(iii) Obligations of the Covered Entity Section
Obligations of a covered entity include informing the pharmacy of
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prescriber eligibility and patient eligibility. 206
From an operational
standpoint, the pharmacy will not agree to independently verify the identity
of every prescriber and patient but needs to be able to rely on this information
that the covered entity provides. 207 A covered entity must verify that it is
authorized: (i) to purchase prescription medications at reduced cost through
the 340B Program for its patients; and (ii) to contract with a licensed
pharmacy to managed and dispense such drugs.208 Importantly, it is the
covered entity's responsibility to inform patients that they are free to choose
their pharmacy, while having the ability to advise patients of possible
discounts through 340B pharmacy locations.209
340B contract pharmacy agreements are typically set up as "ship to, bill
to" arrangements.2 10 Under these arrangements, the drug wholesaler will bill
the covered entity and ship to the pharmacy. 211 These arrangements are
expressly considered and approved in the 2010 HRSA guidance.2 12 To
effectuate a compliant "ship to, bill to" procedure, covered entities must
establish a reliable replenishment process with the wholesaler so that the
pharmacy is not left without its proper stock, which risks leaving the covered
entity on the hook for paying the pharmacy a higher replenishment rate. 213 It
is advisable to identify the approved wholesaler, or supplier, in an exhibit to
the agreement in advance of signing.214 Other exhibits to the agreement
should include an exhibit identifying prescribers and an exhibit identifying
pharmacy locations.215 The latter is required by HRSA policy. Specifically,
HRSA mandates that contract pharmacy agreements list every pharmacy site,
with specific address, that is covered by the agreement.216
In addition to the above, community health centers have added obligations
pursuant to Section 330. These include the requirement to offer eligible

206.
Notice Regarding 340B Drug Pricing Program-Contract Pharmacy Services, 75 Fed.
Reg. 10272 (Mar. 5, 2010).
207.
See id.
208.
See id. at 10273.
209.
See id.
210.
See id. at 10277.
211.
See id.
212.
See id.:

A 'ship to, bill to' procedure is used in which the covered entity purchases the drug;
the manufacturer/wholesaler must bill the covered entity for the drug that it
purchased, but ships the drug directly to the contract pharmacy. [] In cases where
a covered entity has more than one site, it may choose between having each site
billed individually or designating a single covered entity billing address for all
340B drug purchases.
213.
See id. at 10277.
214.
See id. at 10279.
215.
See id.
216.
See id. at 10277.
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patients a sliding fee scale discount on services.217 Further, under Section
330, community health centers are prohibited from offering discounts to third
parties. 218 This requirement is triggered in the fee structure of contracts with
pharmacies and third party benefits managers. 21 9 Both of these Section 330
requirements are discussed in greater detail under the reimbursement and
billing section.
(iv) Obligations of the Pharmacy Section
Obligations of the pharmacy include the very purpose for the agreement,
which is the dispensing of 340B drugs to eligible patients. To accomplish
this, pharmacies need to provide 340B drug inventory maintenance services
to track 340B drug dispensing and replenishment.2 20 Commonly, pharmacies
will use virtual inventories to manage their supply. 221 It is highly
recommended that covered entities meet with pharmacy staff to receive a
demonstration of how that pharmacy runs its inventory and accounts for its
medications.22 2 Pharmacies should represent in the contract their agreement
to maintain a tracking system capable of: tracking 340B drugs received from
the wholesaler; preventing the diversion of 340B drugs to non-eligible
individuals; and verifying that such diversion has not occurred.22 3
(v)

Reimbursement and Billing Section

Payment terms are always instrumental to an arrangement. For 340B
contract pharmacy agreements, the covered entity may pay pharmacies a
dispensing fee and third party benefit managers an administrative fee.
Typically, these fees are flat fees, but there is a trend towards percentagebased fees. Percentage-based fees are generally disfavored by covered
entities. As a practical matter, it is hard to justify a pharmacy earning more
money for dispensing an expensive drug rather than a cheaper drug given the
filling of the prescription entails an equal amount of skill and labor.
Moreover, passing on 340B drug discounts to a pharmacy or vendor is
arguably prohibited by: (1) the 340B Program; (2) the Internal Revenue
Code; and (3) Section 330 of the Public Health Service Act that governs

217. 42 U.S.C. § 254(b)(k)(3) (2010) (detailing the requirements for a successful Section
330 health center).
218. See id.
219. See id.
220. Notice Regarding 340B Drug Pricing Program, supra note 206, at 10275 ("Inventory
and record segregation is one of the many methods that can be used to ensure compliance with
the program guidelines.").
221. See id. at 10274-75.
222. See id. at 10275.
223. See id. at 10278-79.
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community health center operations.
First, the Congressional purpose of giving qualified safety net health care
providers access to 340B discounts is to enable those providers to "reach
more patients" and furnish "more comprehensive services. "224 The 340B
Program was not established to bolster for-profit company's profit
225

Te30

margins.
The 340B Program was enacted by Congress to benefit eligible
safety net providers, their patients, and the taxpayers that support them in an
effort to finance critically needed health care services delivered by these
providers without appropriating additional federal funds. 226 This purpose
cannot be achieved if 340B providers have to pass on the savings they have
received through the 340B Program to third parties.
The difference between a 340B drug's lower acquisition cost and standard
non-340B reimbursement represents the very benefit that Congress intended
to give covered entities when it established the 340B Program. HRSA
explains that if "covered entities were not able to access resources freed up
by the drug discounts when they . .. bill private health insurance, their
programs would receive no assistance from the enactment of section 340B
and there would be no incentive for them to become covered entities. "227
Compensation to a pharmacy dispensing 340B drugs should be fair market
value, and the pharmacy has no legal claim to revenue generated by the cost
spread under 340B. 228 To the extent the financial benefits of 340B wind up
significantly in the hands of vendor pharmacies, the basic purpose of 340B is
undone.
Second, as tax-exempt organizations under Section 501(c)(3) of the
Internal Revenue Code, private community health centers have a special
interest in establishing a prudent procurement process. Section 501(c)(3)
organizations risk revocation of their tax-exempt status if their arrangements
with any vendors unreasonably benefit the vendor, such as by paying service
fees higher than market rates or disproportionate to their value, or through
impermissible revenue sharing arrangements. 229 A prudent procurement

224.
225.
226.
227.

H.R. REP. No. 102-384, pt. 2, at 12 (1992).
See id.
See id.
See HEALTH RES. AND SERV. ADMIN., HEMOPHILIA TREATMENT CENTER MANUAL
FOR PARTICIPATING IN THE DRUG PRICING PROGRAM ESTABLISHED BY SECTION 340B OF THE
PUBLIC
HEALTH SERVICE ACT
(2015),
http://www.hrsa.gov/hemophiliatreatment/
340Bmanual.htm.
228.
See, e.g., KATHERYNE RICHARDSON & DAVID SCHWED, IMPLEMENTING A
COMPREHENSIVE 340B CONTRACTS PHARMACY SERVICE 29 (2004) (Dr. Richardson is a Senior
Director of Apexus).
229.
Section 501(c)(3) requires, as a condition of tax exemption, that the organization's
assets be used exclusively for religious, charitable, or scientific purposes. Although a
charitable organization may contract with and compensate private vendors to provide services,
excessive compensation (or other unreasonable transfer of the organization's assets to the
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process ensures against paying excessive costs and, therefore, is an effective
way for Section 501(c)(3) organizations to show that their vendors are
reasonably paid.
Third, as mentioned previously, Section 330 prohibits a community health
center from providing discounts to third party payers. A community health
center must make "every reasonable effort" to collect payments from third
party payers (without application of any discounts).2 30 Additionally, a
community health center is restrained in how they use revenue generated
based on their Section 330 status. It is a community health center's Section
330 status that makes it eligible for the 340B Program, therefore 340B funds
need to benefit the community health center project. Procurement of services
at fair market value often benefits community health center projects, but there
is little argument for how procuring pharmacy services for above fair market
value would benefit a community health center project. 231 Accordingly, a
340B contract with fees greater than fair market value could jeopardize a
community health center's Section 330 grant.232
Once fees have been successfully negotiated, a community health center
has the added burden of convincing pharmacies to apply the center's sliding
fee scale discount for patients who earn less than two-hundred percent of the
Federal Poverty Level. 233 There are many pharmacies unfamiliar with this
community health center requirement, and they often resist the administrative
work involved in implementing the discount at the counter with individual
patients. That said, it is not the pharmacies' obligation to absorb the patient
discount, but rather the community health center's, so it is a relatively light
lift from the pharmacies to apply patient discounts. Pharmacies can rely on
vouchers or a similar document provided by the community health center to
the patient that would indicate the level of discount to be applied.
(vi) Records and Audits Section
As a covered entity remains liable for any noncompliance, it is
extraordinarily important to include contract provisions that allow a covered
entity to audit the pharmacy.234
As stated earlier, the proposed
MegaGuidance imposes a requirement for covered entities to conduct annual

vendor) can constitute the provision of a private, as opposed to a public, benefit, disqualifying
the organization for tax exemption.
230.
42 U.S.C. § 254b(k)(3)(F) (2010).
231.
See 45 C.F.R. § 74.44(c) (2004).
232.
Notice Regarding 340B Drug Pricing Program, supranote 206, at 10279 (discussing
the importance of complying with the Anti-Kickback Statute in negotiations).
233.
HRSA Health Center Program, ProgramRequirements, U.S. DEPT. OF HEALTH AND
HUMAN SERV., http:/Ibphc.hrsa.gov/programrequirements/index.html (describing the HRSA
program requirements including the sliding fee discounts).
234.
72 Fed. Reg. 1540.
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audits of contract pharmacies using outside independent auditors.235 The
covered entity needs to be able to access pharmacy records upon request.236
Pharmacies may push back and require that audits occur outside of normal
business hours or impose other restrictions that would limit interference with
regular business operations. 237 This pharmacy request for structure is easy to
appreciate, given no one wants to arrive at their pharmacy as a patient for
medication and find inspectors with clipboards or distracted staff members.
In contracting, the covered entity may want to set a timeframe for notifying
the pharmacy of a planned audit and simply state that they will figure out a
mutually-agreeable time within a set number of days from notice. Also, the
covered entity should resist any restrictions on the number of audits they can
perform. It is typical that a 340B contract would state the covered entity's
right to an annual audit, and it is wise to be sure that the covered entity has a
right to audit upon reasonable belief or evidence of a possible diversion or
other violation of the 340B Program.
(vii) Term and Termination Section
The initial term of contracts in the health care field are commonly one year
or more, generally due to any arguable safe harbor under the Anti-Kickback
Statute requiring a one-year term. 238 In the 340B setting, many pharmacies

-

prefer a longer initial term given the cost of starting-up the program. Parties
frequently opt for a provision under which the contract automatically renews
absent notice from one party to another stating the intent to terminate the
arrangement.
Regardless of the duration of the initial and subsequent terms, parties must
be clear about options for immediate termination. As with most - if not all
contracts in the health care arena, parties should be allowed to terminate the
contract immediately if the other party loses its license to operate, files for
bankruptcy, or is excluded from participating in federal health care programs
(i.e., Medicare, Medicaid). For a 340B contract pharmacy arrangement, a
covered entity may want to include as a permissible basis for immediate
termination the reasonable belief that the pharmacy is acting in violation of
the 340B requirements.
Additionally, a community health center may want to ensure that the
contract allows for termination without cause, as alleging a breach of contract
usually comes with the burdens of handling a dispute. Contracts may allow
for termination without cause within a set number of days (e.g., thirty days'
notice), and management will want to consider the pros and cons associated
235.
236.
237.
238.

See 80 Fed. Reg. 52300, 52321.
See Notice Regarding 340B Drug Pricing Program, supra note 206, at 10279.
See id. at 10274.
42 C.F.R. § 1001.952 (2010).
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with being able to get out of an arrangement quickly relative to the pros and
cons associated with the pharmacy being able to cease dispensing of 340B
drugs quickly.
Community health centers would be prudent to include in the termination
section a provision addressing how the parties will handle 340B drug orders
and reimbursement following termination. In other words, the parties should
reconcile 340B drugs dispensed to the community health center's patients
prior to the date of termination against 340B drugs ordered for replenishment
by the community health center and delivered to the pharmacy. The
pharmacy should also reconcile payments due to the community health
center.
(viii) Miscellaneous Sections
As stated earlier, it is important not to skim the miscellaneous provisions
within a contract, particularly when it extends your liabilities. Simple, but
important, contract clauses include notice and amendment. Community
health centers should confirm that the pharmacy may not amend its 340B
dispensing policies without notifying the health center. Additionally, the
community health center will want to be notified if the pharmacy has the right
to and chooses to assign the contract to an affiliate. It is always important to
read indemnification (i.e., hold harmless) clauses carefully to be sure they are
fair and bilateral.
(ix) Other Concerns within 340B Contract Pharmacy Agreements
The covered entity should contract directly with the pharmacy.
Increasingly, third party vendors are trying to be the master of all agreements.
There appears to be a trend in these vendors offering covered entities
administrative services agreements that incorporate the contracts between
vendors and pharmacies, with just an exhibit to the administrative services
agreement identifying which pharmacies are included in the deal. A variation
on this is major pharmacy chains that contract exclusively with a third party
340B vendor, who then reaches out to covered entities and contracts with
these providers without allowing for the covered entity to come into direct
privity of contract with the pharmacy. Efforts to block covered entities from
being in direct contract with 340B contract pharmacies are troubling. Any
attempt to block business transactions raises a red flag.
CONCLUSION

For a community health center not yet enrolled in the Federal 340B Drug
Discount Program, enrollment should be a priority as this program may
support expanded community health center services, in addition to making
affordable outpatient drugs accessible to the community health center's
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uninsured and underinsured patients. 340B contract pharmacy arrangements
can help community health centers expand access for vulnerable patient
populations, but require great scrutiny and ongoing attention.
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